Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02459158 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
A Phase 1 study, sponsored by Meiji Seika Pharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02459158 is a Phase 1 study that has completed, run by Meiji Seika Pharma Co.. The registered enrollment target is 25 participants.
The verdict
NCT02459158, a Phase 1 study, has completed, sponsored by Meiji Seika Pharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP). The secondary objective of this study is to assess the safety and tolerability of ME1100 for the treatment of subjects with MVBP to assess the safety and tolerability of ME1100.
Interventions
- DRUG ME1100 inhalation solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-09 |
| Est. Completion | 2017-03-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02459158
The ClinicalTrials.gov registry entry for NCT02459158 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meiji Seika Pharma Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ME1100 inhalation solution is the first listed.
NCT02459158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02459158 about?
NCT02459158 is a clinical study titled "A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia". This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP). The secondary objective of this study is to assess the safety and tolerability of ME1...
What is the current status of trial NCT02459158?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2015-09. Estimated completion is 2017-03-22.
What interventions are being tested in trial NCT02459158?
The interventions under investigation include: ME1100 inhalation solution (DRUG).
Who is sponsoring clinical trial NCT02459158?
This trial is sponsored by Meiji Seika Pharma Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.